Literature DB >> 27040141

Influence of Genetic Background on Apathy-Like Behavior in Triple Transgenic AD Mice.

R Pardossi-Piquard, I Lauritzen, C Bauer, G Sacco, P Robert, F Checler1.   

Abstract

Apathy is an early and common neuropsychiatric syndrome in Alzheimer's disease (AD) patients. In clinical trials, apathy is associated with decreased motor activity that can be monitored by actigraphy. The triple transgenic mouse AD model (3xTgAD) has been shown to recapitulate the biochemical lesions as well as many of the synaptic and cognitive alterations associated with AD. In the present work we found that these mice also develop an early and consistent apathy-like behavior as evidenced by a drastic decrease in spontaneous activity measured by actimetry. We recently established that these mice also display an intraneuronal accumulation of the β-secretase-derived βAPP fragment (C99) appearing early, in absence of Aβ. Interestingly, we found that the apathy-like behavior observed in 3xTgAD mice was temporally associated with C99 accumulation and synaptic alterations. Since it is well known that the genetic background can strongly influence behavior and can induce transcriptional variability in animal models, we decided to determine the influence of genetic background on the above-described alterations. We backcrossed 3xTgAD mice to C57BL/6 and found that the genetic background had no influence on either C99 accumulation or synaptic plasticity alterations, but strongly affected the apathy-like behavior.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27040141     DOI: 10.2174/1567205013666160404120106

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  8 in total

1.  Genetic reduction of Nrf2 exacerbates cognitive deficits in a mouse model of Alzheimer's disease.

Authors:  Caterina Branca; Eric Ferreira; Thuy-Vi Nguyen; Kristian Doyle; Antonella Caccamo; Salvatore Oddo
Journal:  Hum Mol Genet       Date:  2017-12-15       Impact factor: 6.150

Review 2.  Is γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?

Authors:  Frédéric Checler; Elissa Afram; Raphaëlle Pardossi-Piquard; Inger Lauritzen
Journal:  J Biol Chem       Date:  2021-03-01       Impact factor: 5.157

3.  Genetic Background Influences the Propagation of Tau Pathology in Transgenic Rodent Models of Tauopathy.

Authors:  Tomas Smolek; Veronika Cubinkova; Veronika Brezovakova; Bernadeta Valachova; Peter Szalay; Norbert Zilka; Santosh Jadhav
Journal:  Front Aging Neurosci       Date:  2019-12-11       Impact factor: 5.750

4.  Differences in Immune-Related Genes Underlie Temporal and Regional Pathological Progression in 3xTg-AD Mice.

Authors:  Adelaide Fernandes; Cláudia Caldeira; Carolina Cunha; Elisabete Ferreiro; Ana Rita Vaz; Dora Brites
Journal:  Cells       Date:  2022-01-01       Impact factor: 6.600

5.  Intraneuronal aggregation of the β-CTF fragment of APP (C99) induces Aβ-independent lysosomal-autophagic pathology.

Authors:  Inger Lauritzen; Raphaëlle Pardossi-Piquard; Alexandre Bourgeois; Sophie Pagnotta; Maria-Grazia Biferi; Martine Barkats; Pascale Lacor; William Klein; Charlotte Bauer; Frederic Checler
Journal:  Acta Neuropathol       Date:  2016-04-30       Impact factor: 17.088

6.  Citalopram Ameliorates Impairments in Spatial Memory and Synaptic Plasticity in Female 3xTgAD Mice.

Authors:  Zhang Wei; Guo Junhong; Niu Xiaoyuan; Wang Jie; Wang Zhaojun; Wu Meina; Yang Wei; Zhang Jun; Qi Jinshun
Journal:  Biomed Res Int       Date:  2017-09-18       Impact factor: 3.411

7.  Extracellular vesicles: where the amyloid precursor protein carboxyl-terminal fragments accumulate and amyloid-β oligomerizes.

Authors:  Rocío Pérez-González; Yohan Kim; Chelsea Miller; Javier Pacheco-Quinto; Elizabeth A Eckman; Efrat Levy
Journal:  FASEB J       Date:  2020-08-09       Impact factor: 5.191

Review 8.  Evaluating Circadian Dysfunction in Mouse Models of Alzheimer's Disease: Where Do We Stand?

Authors:  Patrick W Sheehan; Erik S Musiek
Journal:  Front Neurosci       Date:  2020-07-07       Impact factor: 4.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.